TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Technology-Enhanced Quitline Services to Prevent Smoking Relapse
Brief Summary: The purpose of this study is to see if automated telephone monitoring will enhance existing quitline services, such as Alere Wellbeing's Quit For Life program, and help people quit smoking. If successful, this intervention could be incorporated into existing quitline protocols and delivered to millions of people who are trying to quit smoking.


Options:
A: Arm Label: Integrated Cessation Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Tobacco Treatment | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Tobacco Treatment | Intervention Type: BEHAVIORAL; Name: Tobacco Treatment; Assigned to Arm(s): Integrated Cessation Counseling, Usual Care
B: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Telephone behavioral education, Behavioral: Computer behavioral education | Intervention Type: BEHAVIORAL; Name: Telephone behavioral education; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Computer behavioral education; Assigned to Arm(s): Arm 1
C: Arm Label: Group A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Behavioral: Quitline Service + 10 automated monitoring calls | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Behavioral: Quitline service + 20 automated monitoring calls | Intervention Type: BEHAVIORAL; Name: Quitline Service + 10 automated monitoring calls; Assigned to Arm(s): Group B | Intervention Type: BEHAVIORAL; Name: Quitline service + 20 automated monitoring calls; Assigned to Arm(s): Group C
D: Arm Label: Dexpramipexole; Type: EXPERIMENTAL; Interventions: Drug: Dexpramipexole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dexpramipexole; Assigned to Arm(s): Dexpramipexole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Technology-Enhanced Quitline Services to Prevent Smoking Relapse
Brief Summary: The purpose of this study is to see if automated telephone monitoring will enhance existing quitline services, such as Alere Wellbeing's Quit For Life program, and help people quit smoking. If successful, this intervention could be incorporated into existing quitline protocols and delivered to millions of people who are trying to quit smoking.


Options:
A: Arm Label: WhatsApp; Type: EXPERIMENTAL; Interventions: Behavioral: WhatsApp | Arm Label: Facebook; Type: EXPERIMENTAL; Interventions: Behavioral: Facebook | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: WhatsApp; Assigned to Arm(s): WhatsApp | Intervention Type: BEHAVIORAL; Name: Facebook; Assigned to Arm(s): Facebook
B: Arm Label: 8 weeks transdermal nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal nicotine patch | Arm Label: 24 weeks transdermal nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal nicotine patch | Arm Label: 52 weeks transdermal nicotine; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine patch | Intervention Type: DRUG; Name: Transdermal nicotine patch; Assigned to Arm(s): 24 weeks transdermal nicotine, 52 weeks transdermal nicotine, 8 weeks transdermal nicotine
C: Arm Label: SBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Behavioral Therapy | Arm Label: CBT; Type: EXPERIMENTAL; Interventions: Behavioral: CBT addressing postpartum mood and weight concerns | Intervention Type: BEHAVIORAL; Name: CBT addressing postpartum mood and weight concerns; Assigned to Arm(s): CBT | Intervention Type: BEHAVIORAL; Name: Supportive Behavioral Therapy; Assigned to Arm(s): SBT
D: Arm Label: Group A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Behavioral: Quitline Service + 10 automated monitoring calls | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Behavioral: Quitline service + 20 automated monitoring calls | Intervention Type: BEHAVIORAL; Name: Quitline Service + 10 automated monitoring calls; Assigned to Arm(s): Group B | Intervention Type: BEHAVIORAL; Name: Quitline service + 20 automated monitoring calls; Assigned to Arm(s): Group C

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomized Comparison of Pancreatic Stump Closure Techniques Utilizing an Autologous Falciform Patch and Fibrin Glue Compared to Standard Closure Following Distal Pancreatectomy With or Without Splenectomy
Brief Summary: The purpose of this trial is to determine whether the use of an autologous falciform ligament patch combined with fibrin glue will reduce the rate of pancreatic fistula in patients completing distal pancreatectomy. The hypothesis for the current trial is: Autologous falciform patch closure with fibrin glue will result in a 50% decrease in fistula formation postoperatively. The primary end point will be the development of pancreatic fistula using the ISGPF definition of pancreatic fistula1. (Drain output of any measurable volume of fluid on or after postop day #3 with an amylase content greater than three times serum amylase). Secondary end points will include length of postoperative hospital stay, percutaneous intervention rates, re-operation rates, morbidity to include delayed gastric emptying, wound infection, intraabdominal abscess, postoperative hemorrhage and 30-day mortality.(Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: An international study group (ISGPF) definition. The Journal of Surgery, 2005;138:8-13).


Options:
A: Arm Label: Hemopatch; Type: EXPERIMENTAL; Interventions: Device: Hemopatch | Intervention Type: DEVICE; Name: Hemopatch; Assigned to Arm(s): Hemopatch
B: Arm Label: Tachocomb; Type: ACTIVE_COMPARATOR; Interventions: Device: Tachocomb | Arm Label: PGA; Type: ACTIVE_COMPARATOR; Interventions: Device: Polyglycolic acid (PGA) (Neoveil) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Tachocomb; Assigned to Arm(s): Tachocomb | Intervention Type: DEVICE; Name: Polyglycolic acid (PGA) (Neoveil); Assigned to Arm(s): PGA
C: Arm Label: Patch and glue arm; Type: EXPERIMENTAL; Interventions: Procedure: Falciform patch and fibrin glue application | Arm Label: stapled /sutured pancreatic closure; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard pancreatic closure | Intervention Type: PROCEDURE; Name: Falciform patch and fibrin glue application; Assigned to Arm(s): Patch and glue arm | Intervention Type: PROCEDURE; Name: standard pancreatic closure; Assigned to Arm(s): stapled /sutured pancreatic closure
D: Arm Label: application of TachoSil®; Type: EXPERIMENTAL; Interventions: Drug: Fibrinogen/thrombin-coated collagen patch | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Fibrinogen/thrombin-coated collagen patch; Assigned to Arm(s): application of TachoSil®

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Lower Limb Remote Preconditioning on Myocardial Injury in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery
Brief Summary: In recent several clinical trials, remote preconditioning showed very powerful myocardial protection. However, the myocardial protective effect by remote preconditioning was not evaluated on the patients undergoing off pump coronary artery bypass graft surgery (OPCAB).

The investigators hypothesized that the lower limb remote preconditioning could protect the myocardium during the OPCAB. In this study, the investigators will try to evaluate whether remote preconditioning could induce myocardial protection on the OPCAB patients.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: remote ischemic postconditioning | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: remote ischemic postconditioning | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Procedure: remote ischemic postconditioning | Intervention Type: PROCEDURE; Name: remote ischemic postconditioning; Assigned to Arm(s): 1, 2, 3
B: Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): N/A
C: Arm Label: Remote preconditioning; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote ischemic preconditioning | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Placebo | Intervention Type: PROCEDURE; Name: Remote ischemic preconditioning; Assigned to Arm(s): Remote preconditioning | Intervention Type: PROCEDURE; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: PROCEDURE; Name: Ischemic preconditioning; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Forearm ischemic exercise; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Annexin A5 scintigraphy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Diazoxide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glibenclamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: adenosine; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Heparin Versus Prostacyclin in Continuous Hemodiafiltration for Acute Renal Failure: Effects on Platelet Responsiveness in the Systemic Circulation and Across the Filter.
Brief Summary: The researchers investigated the influence of a prostacyclin analogue (PGIA) versus unfractionated heparin (UFH) on ex vivo platelet function, during continuous venovenous hemodiafiltration.


Options:
A: Arm Label: oXiris; Type: ACTIVE_COMPARATOR; Interventions: Device: oXiris | Arm Label: ST150; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: oXiris; Assigned to Arm(s): oXiris
B: Arm Label: 1 prostacyclin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: prostacyclin | Arm Label: 2 heparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: heparin | Intervention Type: DRUG; Name: prostacyclin; Assigned to Arm(s): 1 prostacyclin group | Intervention Type: DRUG; Name: heparin; Assigned to Arm(s): 2 heparin group
C: Arm Label: Nafamostat mesilate group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nafamostat mesilate | Arm Label: No anticoagulation group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Nafamostat mesilate; Assigned to Arm(s): Nafamostat mesilate group | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): No anticoagulation group
D: Arm Label: citrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: trisodium citrate | Arm Label: nadroparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: nadroparin | Intervention Type: DRUG; Name: trisodium citrate; Assigned to Arm(s): citrate | Intervention Type: DRUG; Name: nadroparin; Assigned to Arm(s): nadroparin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Heparin Versus Prostacyclin in Continuous Hemodiafiltration for Acute Renal Failure: Effects on Platelet Responsiveness in the Systemic Circulation and Across the Filter.
Brief Summary: The researchers investigated the influence of a prostacyclin analogue (PGIA) versus unfractionated heparin (UFH) on ex vivo platelet function, during continuous venovenous hemodiafiltration.


Options:
A: Arm Label: citrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: trisodium citrate | Arm Label: nadroparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: nadroparin | Intervention Type: DRUG; Name: trisodium citrate; Assigned to Arm(s): citrate | Intervention Type: DRUG; Name: nadroparin; Assigned to Arm(s): nadroparin
B: Arm Label: heparin; Type: ACTIVE_COMPARATOR; Interventions: Other: regional anticoagulation with citrate | Arm Label: Citrate; Type: ACTIVE_COMPARATOR; Interventions: Other: HfCitPre | Intervention Type: OTHER; Name: regional anticoagulation with citrate; Assigned to Arm(s): heparin | Intervention Type: OTHER; Name: HfCitPre; Assigned to Arm(s): Citrate
C: Arm Label: Nafamostat mesilate group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nafamostat mesilate | Arm Label: No anticoagulation group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Nafamostat mesilate; Assigned to Arm(s): Nafamostat mesilate group | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): No anticoagulation group
D: Arm Label: 1 prostacyclin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: prostacyclin | Arm Label: 2 heparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: heparin | Intervention Type: DRUG; Name: prostacyclin; Assigned to Arm(s): 1 prostacyclin group | Intervention Type: DRUG; Name: heparin; Assigned to Arm(s): 2 heparin group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Heparin Versus Prostacyclin in Continuous Hemodiafiltration for Acute Renal Failure: Effects on Platelet Responsiveness in the Systemic Circulation and Across the Filter.
Brief Summary: The researchers investigated the influence of a prostacyclin analogue (PGIA) versus unfractionated heparin (UFH) on ex vivo platelet function, during continuous venovenous hemodiafiltration.


Options:
A: Arm Label: 1 prostacyclin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: prostacyclin | Arm Label: 2 heparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: heparin | Intervention Type: DRUG; Name: prostacyclin; Assigned to Arm(s): 1 prostacyclin group | Intervention Type: DRUG; Name: heparin; Assigned to Arm(s): 2 heparin group
B: Arm Label: AKI requring CRRT and use regional citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Procedure: Continuous renal replacement therapy with regional citrate anticoagulation | Arm Label: AKI requring CRRT and not use regional citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Procedure: Continuous renal replacement therapy with no anticoagulation or heparin | Intervention Type: PROCEDURE; Name: Continuous renal replacement therapy with regional citrate anticoagulation; Assigned to Arm(s): AKI requring CRRT and use regional citrate anticoagulation | Intervention Type: PROCEDURE; Name: Continuous renal replacement therapy with no anticoagulation or heparin; Assigned to Arm(s): AKI requring CRRT and not use regional citrate anticoagulation
C: Arm Label: heparinized saline priming group; Type: EXPERIMENTAL; Interventions: Drug: heparinized saline priming group | Arm Label: nafamostat infusion group after heparinized saline priming; Type: ACTIVE_COMPARATOR; Interventions: Drug: nafamostat infusion after heparinized saline priming | Intervention Type: DRUG; Name: heparinized saline priming group; Assigned to Arm(s): heparinized saline priming group | Intervention Type: DRUG; Name: nafamostat infusion after heparinized saline priming; Assigned to Arm(s): nafamostat infusion group after heparinized saline priming
D: Arm Label: High citrate group; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Arm Label: Low citrate group; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): High citrate group, Low citrate group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing First Metatarsal Osteotomy (Bunionectomy)
Brief Summary: After undergoing bunion surgery, patients are given a pain medicine injection that may last for up to several days or a placebo. Their pain and pain medicine use is then monitored.


Options:
A: Arm Label: SKY0402 high dose; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: SKY0402 middle dose; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: SKY0402 low dose; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: Bupivacaine HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine HCl | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): SKY0402 high dose, SKY0402 low dose, SKY0402 middle dose | Intervention Type: DRUG; Name: Bupivacaine HCl; Assigned to Arm(s): Bupivacaine HCl
B: Arm Label: Bupivacaine HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine HCl | Arm Label: SKY0402; Type: OTHER; Interventions: Drug: SKY0402 | Intervention Type: DRUG; Name: Bupivacaine HCl; Assigned to Arm(s): Bupivacaine HCl | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): SKY0402
C: Arm Label: IV morphine sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV morphine sulfate | Arm Label: EXPAREL; Type: EXPERIMENTAL; Interventions: Drug: EXPAREL (bupivacaine liposome injectable suspension) | Intervention Type: DRUG; Name: IV morphine sulfate; Assigned to Arm(s): IV morphine sulfate | Intervention Type: DRUG; Name: EXPAREL (bupivacaine liposome injectable suspension); Assigned to Arm(s): EXPAREL
D: Arm Label: Sky0402; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): Sky0402 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy
Brief Summary: Patients will get an injection of either SKY0402 or placebo during hemorrhoid surgery, and their pain and pain medicine use will be monitored.


Options:
A: Arm Label: Bupivacaine and low dose SKY0402; Type: N/A; Interventions: Drug: Questionnaire and Physical Exam | Arm Label: Bupivacaine and high dose SKY0402; Type: N/A; Interventions: Drug: Questionnaire and Physical Exam | Arm Label: Bupivacaine; Type: N/A; Interventions: Drug: Questionnaire and Physical Exam | Arm Label: High dose SKY0402; Type: N/A; Interventions: Drug: Questionnaire and Physical Exam | Intervention Type: DRUG; Name: Questionnaire and Physical Exam; Assigned to Arm(s): Bupivacaine, Bupivacaine and high dose SKY0402, Bupivacaine and low dose SKY0402, High dose SKY0402
B: Arm Label: IV Morphine Sulfate or Sponsor-approved Equivalent; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV morphine sulfate or Sponsor-approved equivalent | Arm Label: EXPAREL; Type: EXPERIMENTAL; Interventions: Drug: EXPAREL | Intervention Type: DRUG; Name: IV morphine sulfate or Sponsor-approved equivalent; Assigned to Arm(s): IV Morphine Sulfate or Sponsor-approved Equivalent | Intervention Type: DRUG; Name: EXPAREL; Assigned to Arm(s): EXPAREL
C: Arm Label: SKY0402; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): SKY0402 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Bupivacaine HCl 105mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine HCl | Arm Label: SKY0402 low dose; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: SKY0402 Middle dose; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: SKY0402 High dose; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Intervention Type: DRUG; Name: Bupivacaine HCl; Assigned to Arm(s): Bupivacaine HCl 105mg | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): SKY0402 High dose, SKY0402 Middle dose, SKY0402 low dose

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravenous Oxytocin Use to Decrease Blood Loss During Cesarean Section. What is the Optimal Dose: A Randomized Blinded Trial
Brief Summary: The goal of this study is to determine the best dose of a drug called oxytocin, that is usually used to stop bleeding during a delivery, when used during a cesarean delivery. It will be administered during cesarean section in order to decrease the amount blood loss. The investigators are proposing to have 3 groups of subjects each given a different safe dose of oxytocin and then to assess the effectiveness of each regimens on the amount blood lost during cesarean sections.This will let use know which is the best lowest dose needed.


Options:
A: Arm Label: oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: oxytocin2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: oxytocin3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): oxytocin, oxytocin2, oxytocin3
B: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin
C: Arm Label: Oxytocin 10 units/500cc; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 40 units/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 80U/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin 10 units/500cc, Oxytocin 40 units/500cc, Oxytocin 80U/500cc
D: Arm Label: Arm A: sublingual misoprostol 600µg; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Arm B: 10 IU Oxytocin; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Arm A: sublingual misoprostol 600µg

Answer: A